Evidence check: Pharmakogenetik Medicheck in the context of gut health

The pharmacogenetics Medicheck analyzes genetic variants in drug-metabolizing enzymes (e.g., CYP450, TPMT). In the context of gut health, direct evidence is weak. While drugs like proton pump inhibitors (PPIs) or antibiotics can alter the gut microbiome, and their metabolism is partly genetically controlled (e.g., CYP2C19 for PPIs), the clinical relevance for individual gut health is unclear. Most studies are mechanistic or GWAS-based with small effect sizes. A PGx test may offer clues about drug tolerance but does not replace stool analysis or dietary advice. Consumers should be aware: its predictive power for specific gut issues is limited, and many claims are marketing-driven. A holistic approach (microbiome, nutrition, lifestyle) remains essential.